Department of Breast Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
Department of Oncology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
Clin Chim Acta. 2018 Aug;483:209-215. doi: 10.1016/j.cca.2018.05.005. Epub 2018 May 5.
There are conflicting reports about the role of histone deacetylase 1 (HDAC1) in breast cancer prognosis. Here, we conducted a meta-analysis to investigate the prognostic significance of HDAC1 in breast cancer.
We searched different databases to identify studies evaluating the association between HDAC1 expression and its prognostic value in breast cancer. The pooled hazard ratios (HRs) and odds radios (ORs) with 95% confidence intervals (95% CIs) were calculated from these studies to assess specific correlation.
Our meta-analysis of four databases identified 7 eligible studies with 1429 total patients. We found that HDAC1 over-expression did not correlate with disease-free survival (DFS) and overall survival (OS) in breast cancer. Subgroup analysis indicated an association between up-regulated HDAC1 expression and better OS (HR = 0.47, 95% CI: 0.23-0.97; P = 0.04) in Asian breast cancer patients. However, false-positive report probability (FPRP) analysis and trial sequential analysis (TSA) indicated that the results need further validation. Furthermore, HDAC1 over-expression was associated with positive estrogen receptor (ER) expression (OR, 3.30; 95% CI, 1.11-9.83; P = 0.03) and negative human epidermal growth factor receptor 2 (HER2) expression (OR, 1.79; 95% CI, 1.22-2.61; P = 0.003), but there were no significant differences between patients based on age, tumor size, lymph node metastasis, nuclear grade, or progesterone receptor (PR) expression.
Overall, our meta-analysis demonstrated an association between increased HDAC1 expression and better OS in Asian breast cancer patients. In addition, HDAC1 over-expression correlated with positive ER and negative HER2 expression in breast cancer. However, researches in large patients' randomised controlled trials (RCTs) are needed to confirm the results.
组蛋白去乙酰化酶 1（HDAC1）在乳腺癌预后中的作用存在争议的报告。在这里，我们进行了一项荟萃分析，以研究 HDAC1 在乳腺癌中的预后意义。
我们搜索了不同的数据库，以确定评估 HDAC1 表达与乳腺癌预后之间关联的研究。从这些研究中计算合并的风险比（HRs）和优势比（ORs）及其 95％置信区间（95％CI），以评估特定相关性。
我们对四个数据库的荟萃分析确定了 7 项符合条件的研究，共纳入了 1429 名患者。我们发现 HDAC1 过表达与乳腺癌无病生存率（DFS）和总生存率（OS）无关。亚组分析表明，亚洲乳腺癌患者中上调的 HDAC1 表达与更好的 OS 相关（HR=0.47，95％CI：0.23-0.97；P=0.04）。然而，假阳性报告概率（FPRP）分析和试验序贯分析（TSA）表明，结果需要进一步验证。此外，HDAC1 过表达与雌激素受体（ER）阳性表达相关（OR，3.30；95％CI，1.11-9.83；P=0.03）和人类表皮生长因子受体 2（HER2）阴性表达相关（OR，1.79；95％CI，1.22-2.61；P=0.003），但在年龄、肿瘤大小、淋巴结转移、核分级或孕激素受体（PR）表达方面，患者之间没有显着差异。
总体而言，我们的荟萃分析表明，亚洲乳腺癌患者中 HDAC1 表达增加与 OS 改善相关。此外，HDAC1 过表达与乳腺癌中 ER 阳性和 HER2 阴性表达相关。然而，需要在大患者随机对照试验（RCTs）中进行研究，以确认结果。
